Two distinct pathways of p16 gene inactivation in gallbladder cancer

Hiroyuki Tadokoro, Takako Shigihara, Tomomi Ikeda, Masaru Takase, Masafumi Suyama

Hiroyuki Tadokoro, Masafumi Suyama, Department of Gastroenterology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 136-0075, Japan
Takako Shigihara, Tomomi Ikeda, Biochemical Research Center, Division of Molecular and Biochemical Research, Juntendo University School of Medicine, Tokyo 136-0075, Japan
Masaru Takase, Department of Human Pathology, Juntendo University School of Medicine, Tokyo 136-0075, Japan
Correspondence to: Hiroyuki Tadokoro, MD, Department of Gastroenterology, Juntendo Tokyo Koto Geriatric Medical Center, 3-3-20 Shinsuna, Koto-ku, Tokyo 136-0075, Japan
Telephone: +81-356-323111 Fax: +81-356-323728
Received: July 19, 2007 Revised: September 12, 2007

Abstract

AIM: To examine the mechanism of inactivation of the p16 gene in gallbladder cancer, and to investigate p16 alterations and their correlation with clinicopathological features.

METHODS: Specimens were collected surgically from 51 patients with gallbladder cancer. We evaluated the status of protein expression, loss of heterozygosity (LOH), homozygous deletion and promoter hypermethylation using immunohistochemistry, microsatellite analysis, quantitative real-time polymerase chain reaction (PCR) and methylation-specific PCR, respectively. In addition, mutations were examined by direct DNA sequencing.

RESULTS: Homozygous deletions of the p16 gene exon2, LOH at 9p21-22, p16 promoter hypermethylation, and loss of p16 protein expression were detected in 26.0% (13/50), 56.9% (29/51), 72.5% (37/51) and 62.7% (32/51), respectively. No mutations were found. LOH at 9p21 correlated with the loss of p16 protein expression (P < 0.05). Homozygous deletion of the p16 gene, a combination LOH and promoter hypermethylation, and multiple LOH were significantly correlated with the loss of p16 protein expression (P < 0.05). LOH at 9p21 and promoter hypermethylation of the p16 gene were detected in 15.4% (2/13) and 92.3% (12/13) of the tumors with homozygous deletion of the p16 gene, respectively. P16 alterations were not associated with clinicopathological features.

CONCLUSION: Our results suggest that LOH and homozygous deletion may be two distinct pathways in the inactivation of the p16 gene. Homozygous deletion, a combination of LOH and promoter hypermethylation, and multiple LOH are major mechanisms of p16 inactivation in gallbladder cancer.

INTRODUCTION

Gallbladder carcinoma is a highly malignant neoplasm with a poor prognosis, and most patients are diagnosed at an already advanced stage[1-3]. Gallbladder carcinoma is a relatively common cancer and is the sixth highest cause of cancer death in Japanese women.

Several genes have been implicated in the tumorigenesis of gallbladder cancers, including K-ras, cerbB2, p53[4,5], p16Nkx2/CDKN2, and the fragile histidine triad (FHIT)[6]. Genetic alterations in the 9p21 chromosomal region have been linked to malignant progression.

The p16 gene, located on chromosome 9p21, encodes a critical negative regulator of cell cycle progression and is inactivated in various cancers. The p16 gene is an important tumor suppressor gene, which interacts strongly with cyclin-dependent kinases 4 and 6, and inhibits their ability to interact with cyclin D[7]. p16 induces cell cycle arrest at G1 and G2/M checkpoints, which blocks cells from phosphorylating retinoblastoma protein 1, and prevents cells from exiting the G1 phase of the cell cycle[8]. p16 can act as a negative regulator of normal cell proliferation. Inactivation of the p16 gene plays an important role in tumorigenesis. p16 inactivation by loss of heterozygosity (LOH) and point mutations has been reported in biliary tract cancers[9] and intrahepatic cholangiocarcinoma[10].

Aberrant promoter methylation is an important mechanism in silencing cancer-related genes during the process of carcinogenesis. Epigenetic inactivation of tumor suppressor genes has been commonly reported in various tumors[11]. Promoter hypermethylation, as
well as gene deletions and point mutations, has been shown to be a major mechanism of p16 inactivation\textsuperscript{[12,13]}. Hypermethylation of the CpG islands of the p16 gene promoter region has been reported in various types of tumor.

The main modes of p16 gene inactivation in gallbladder carcinoma are known to include LOH, mutation and hypermethylation\textsuperscript{[12,14]}. Homozygous deletion of the p16 gene has not previously been investigated in gallbladder cancer. Therefore, we sought to comprehensively study genetic and epigenetic alterations of p16, including homozygous deletion of the p16 gene, and the relationship between these abnormalities and clinicopathological features.

**MATERIALS AND METHODS**

**Tissue specimens**

Paraffin-embedded tissue samples were obtained from 51 patients who underwent surgical resection at Juntendo University School of Medicine, Japan, between April 1996 and April 2005. Gallbladder carcinoma patients consisted of 25 women and 26 men, ranging in age from 36 to 94 (mean, 65.1) years. Their tumors consisted of 46 adenocarcinomas and five adenosquamous carcinomas. The adenocarcinomas included 39 well-to-moderately differentiated and seven poorly differentiated tumors. Most of the patients had advanced gallbladder carcinoma, with invasion of the subserosa (n = 22, 43.1%) and serosa (n = 18, 35.3%), while the other 11 patients (19.6%) had early gallbladder carcinoma (mucosa or muscularis propria invasion). All histological slides were reviewed by M.T. and H.T. and were classified based on the WHO classification of gallbladder carcinoma. Medical records were available for all patients.

**Immunohistochemical analysis**

Immunohistochemistry was performed using anti-p16 (F-12; 1:500 dilution; Santa Cruz Biochemistry, Santa Cruz, CA, USA) and an automated slide staining system (NexES IHC, Ventana, AZ, USA) according to the manufacturer’s instructions. P16 immunostaining was performed within 2 weeks of sectioning, because reactivity decreased over time after preparation. Normal lymphocytes and intrahepatic bile ducts were positive controls for p16. The percentage of positive nuclei was scored as follows: -, 0%-10%, + 1%-25%, ++, 25%-50%, and ++++, > 50% positive cells. Scores of +, ++ and ++++ were considered to represent positive immunostaining, while - was deemed to be negative.

**DNA extraction**

Formalin-fixed, paraffin-embedded tissue blocks were used. Serial 10-μm sections were cut from each block and stained with hematoxylin and eosin to locate the tumor and non-neoplastic tissue before DNA extraction. Sections were cut, deparaffinized, and microdissected with an 18-gauge needle. The microdissected tissues were digested overnight at 55°C in buffer (1% Tween 20, 10 mmol/L Tris-HCl, pH 8, 1 mmol/L EDTA, and 100 μg/mL proteinase K). The lysates were heated at 95°C for 10 min and stored at 4°C until analyzed by polymerase chain reaction (PCR).

**Methylation assay**

DNA methylation was investigated using an EZ DNA methylation kit (Zymo Research, CA, USA), according to the manufacturer’s protocol. Microdissected genomic DNA (1 ng) was denatured with M-dilution buffer at 37°C for 15 min, followed by incubation with CT conversion reagent at 50°C for 16 h in the dark. After treatment, the DNA was purified using M-binding buffer, incubated with M-desulphonation buffer at room temperature for 15 min, washed with wash buffer, and finally resuspended in M-elution buffer.

Primers for the p16 gene were 5’-TTATTAGAGGG TGGGGTGATTGT-3’ (sense) and 5’-CCACCTAAAT CAACCTCCAACCA-3’ (antisense) for the unmethylated reactions, and 5’-TTATTAGAGGGTGGGCGGATCG C-3’ (sense) and 5’-GACCCGAAACCGGCCGTAA-3’ (antisense) for the methylated reactions, as described previously\textsuperscript{[15]}. PCR reactions were started by denaturation at 95°C for 5 min, followed by 40-45 cycles of 94°C for 30 s, 65°C (for methylated p16) or 60°C (for unmethylated p16) for 45 s, and 72°C for 60 s, with a final extension at 72°C for 10 min. PCR products were analyzed by electrophoresis on a 3% agarose gel, and visualized by ethidium bromide staining. DNA from the Raji cell line was used as a positive control. Distilled water was used as a negative control.

**LOH analysis**

Paired normal and tumor DNA samples were amplified by hot-start PCR, using locus-specific flanking primer pairs for five fluorescently labeled microsatellite markers, D9S171-FAM, D9S1748-FAM, D9S942-NEX, D9S974-NED, and D9S1749-NED (Figure 1). Primer sequences were obtained from the NCBI UniSTS database (http://www.ncbi.nlm.nih.gov/). Markers mapping to the chromosome 9p21-22 region were used. D9S1748, D9S942 and D9S974 are within a coding sequence of the p16 gene. D9S1749 is telomeric to p16 and D9S171 is centromeric to p16. PCR was performed with an initial denaturation at 95°C for 15 min, followed by 36 cycles of denaturation at 95°C for 30 s, annealing at 58°C (D9S171, D9S1748, D9S942, D9S974) or 55°C (D9S1749) for 45 s, and extension at 72°C for 60 s, and final extension at 72°C for 10 min. After PCR, samples were diluted at 1:7 in formamide, heated to 95°C for 2 min, chilled on ice, and analyzed with Genescan software on an ABI PRISM 310 genetic analyzer (PE-Applied Biosystems, Foster City, CA, USA). Allelic ratios in both normal and tumor samples were calculated and compared. The area under each peak, representing each allele in the microsatellite pair, was obtained. LOH was defined as a > 50% reduction in the tumor peak compared to that of the corresponding normal tissue. Additional bands that were not seen on normal DNA, but were observed in tumor samples, were considered evidence of microsatellite instability (MSI).

**Detection of homozygous deletion of p16 exon2**

Homozygous gene deletion and gene dosage of p16 exon2
in gallbladder cancer were determined using a TaqMan-based real-time PCR method. Briefly, p16 gene exon2 and the GAPDH gene were amplified in a monoplex assay. The primer sequences for detecting p16 exon2 were 5’-AGCTTCCTTTCCGTCATGC-3’ (sense) and 5’-TCATGACCTGCCAGAGAAG-3’ (antisense). The primer sequences for detecting the GAPDH gene were 5’-GCATCCTGGGCTACACTGAG-3’ (sense) and 5’-AGGTGGAGGAGTGGGTGTC-3’ (antisense). The probe sequence for p16 gene exon2 was FAM-TGGCTCTG, and the probe sequence for the GAPDH gene was FAM-CTCCTCTG (the three FAM-labeled probes were manufactured by Roche Applied Science, Mannheim, Germany). The real-time PCR was performed in a 25 μL final volume containing 12.5 μL of Premix Ex Taq (Perfect Real Time; Takara, Kyoto, Japan), 50 ng DNA template, 10 μmol/L of each primer, 10 μmol/L Universal Library Probe, 0.5 μL ROX reference dye (50 ×), and 5.75 μL distilled water. The thermal cycling conditions on the ABI PRISM 7500 instrument were set to 10 s at 95°C, followed by 40 cycles of 5 s at 95°C, alternating with 34 s at 60°C. DNA from lymphocytes isolated from a paraffin block was used as a positive control. All reactions were done in triplicate. Normalized gene dosage ratios were interpreted as follows: 0-0.3, homozygous deletion; 0.31-0.69, under-representation (of the test gene, relative to the reference gene); 0.7-1.49, retention of copy number; and > 1.5 over-representation.

**Mutation analysis**

Mutation analysis was performed for the p16 gene (exons 1α, 2 and 3). Primer sequences and PCR conditions were as described previously [16,17] (Table 1). Amplification was performed using a Perkin Elmer GeneAmp 9600 Thermal cycler. After visualizing the PCR products in a 3% agarose gel, an aliquot (5 μL) of the PCR product was treated at 37°C for 15 min with 1 μL ExoSAP-IT (GE Healthcare Biosciences, Piscataway, NJ, USA), followed by inactivation at 80°C for 15 min. Part of this mix (6 μL) was directly sequenced using a BigDye Terminator v1.1 Cycle Sequencing kit (Applied Biosystems Japan, Chiba) on an automated sequencer (ABI PRISM 3100 Genetic analyzer; Perkin-Elmer, Japan).

**Statistical analysis**

Frequency distributions were analyzed by the χ² test. Correlations were examined between alterations of p16 and p16 expression, or between alterations of p16 and clinicopathological parameters. P < 0.05 was deemed statistically significant.

**RESULTS**

**Immunohistochemical analysis**

Loss of p16 protein expression occurred in 62.7% (32/51) of gallbladder cancer patients. Staining for p16 was weak in 13.7% (7/51) of patients, moderate in 17.6% (9/51), and strong in only 9.8% (5/51) of patients (Figure 1). There was no significant difference in p16 protein expression according to patient age, gender, tumor stage, T factor, N factor or histology (Table 2).

**p16 status**

LOH at 9p21-22 was detected in at least one marker in 56.9% (29/51) of patients. LOH occurred in 11.8%, 27.5%, 11.8%, 13.7% and 39.2% of patients who were positive for the markers D9S171, D9S1748, D9S942, D9S974 and D9S1749, respectively. Approximately 29.4% of the cases presented with LOH in a single marker, 11.8% with LOH in two markers, and 15.7% with LOH in three or more markers. LOH at the three markers D9S1748,
D9S942 and D9S974 within a coding sequence of the p16 gene was 37.3% in total. Representative examples of LOH at D9S942 and D9S748 are shown in Figure 2.

Gene dosage of p16 exon 2 was successfully measured in 50 of 51 cases. Homozygous deletion of p16 exon2 was detected in 13 of 50 (26%) tumors. Overall the p16 gene was altered by homozygous deletion and LOH in 56.9% (29/51) of the tumors, indicating that alterations at this locus are involved in the vast majority of the tumors. In our analysis, LOH at 9p21-22 and homozygous deletion of p16 exon 2 were not associated with demographic variables such as age, gender, tumor histology and stage, T factor or N factor (Table 2).

p16 methylation status
Hypermethylation of the p16 gene was observed in 72.5% (37/51) of the patients (Figure 3). The relationship between p16 hypermethylation and various clinicopathological features was analyzed statistically. There was no significant correlation with the clinicopathological parameters assessed, including age, gender, tumor stage, T factor or N factor (Table 2). P16 methylation was found in 37 of 51 gallbladder cancer patients (72.5%), and loss of p16 protein expression was detected in 20 of the 37 tumors (54.1%) showing p16 hypermethylation. Our data showed that P16 protein expression was not significantly correlated with p16 hypermethylation.

p16 mutations
In tumors without homozygous deletions, exons 1α, 2 and 3 were amplified. In five cases, which were non-informative for the markers investigated, constitutive DNA was not available. No mutations were detected in exons 1α, 2 or 3.

Table 2 Association between p16 alterations and clinicopathological variables in gallbladder cancers

| Clinicopathological variables | p16 protein expression | Methylation of p16 | LOH at 9p21-22 | Homozygous deletion of p16 gene |
|------------------------------|------------------------|-------------------|----------------|-----------------------------|
|                              | Absent | Present | P       | Absent | Present | P       | Retention | LOH            | Absent | Present | P       |
| Age                          |        |         |         |        |         |         |           |                |        |         |         |
| < 65                         | 13     | 7       | 0.789   | 5      | 15      | 0.753   | 10        | 10             | 0.427  | 13       | 6       | 0.481   |
| > 65                         | 19     | 12      |         | 9      | 22      |         | 12        | 19             |        | 24       | 7       |
| Gender                       |        |         |         |        |         |         |           |                |        |         |         |
| Female                       | 14     | 11      | 0.329   | 6      | 19      | 0.588   | 10        | 15             | 0.657  | 20       | 4       | 0.148   |
| Male                         | 18     | 8       |         | 8      | 18      |         | 12        | 14             |        | 17       | 9       |
| Tumor type                   |        |         |         |        |         |         |           |                |        |         |         |
| Adenocarcinoma               | 28     | 18      | 0.401   | 14     | 32      | 0.148   | 19        | 27             | 0.423  | 35       | 10      | 0.068   |
| Adenosquamous                | 4      | 1       |         | 0      | 5       |         | 3         | 2              |        | 2        | 3       |
| Differentiation grade        |        |         |         |        |         |         |           |                |        |         |         |
| Well-Moderate                | 22     | 17      | 0.144   | 12     | 27      | 0.907   | 18        | 21             | 0.115  | 29       | 10      | 0.16    |
| Poor                         | 6      | 1       |         | 2      | 5       |         | 1         | 6              |        | 6        | 0       |
| Stage                        |        |         |         |        |         |         |           |                |        |         |         |
| 0 and IA, 1A, 1B             | 15     | 13      | 0.135   | 9      | 19      | 0.407   | 15        | 13             | 0.097  | 20       | 7       | 0.99    |
| II A and II B                | 17     | 6       |         | 5      | 18      |         | 7         | 16             |        | 17       | 6       |
| T factor                     |        |         |         |        |         |         |           |                |        |         |         |
| Tis and T1                   | 6      | 6       | 0.296   | 3      | 9       | 0.828   | 8         | 4              | 0.060  | 11       | 1       | 0.11    |
| T2 and T3                    | 26     | 13      |         | 11     | 28      |         | 14        | 25             |        | 26       | 12      |
| N factor                     |        |         |         |        |         |         |           |                |        |         |         |
| N0                           | 21     | 16      | 0.150   | 9      | 28      | 0.416   | 19        | 18             | 0.054  | 28       | 8       | 0.329   |
| N1                           | 11     | 3       |         | 5      | 9       |         | 3         | 11             |        | 9        | 5       |

All P values were revealed by χ²-test.

Figure 2 Representative example of the results of microsatellite analysis showing LOH at D9S1748 and LOH at D9S942 (right, case 25; left, case 45). The scales on the top and left side of each figure represent the size (bp) and the intensity, respectively. N: Normal; T: Tumor.
Positive 16
9
16

U
M
6
9
16
9
M
T15
20
M
U
M
3
3
U
T12
M
3
2
0.0146
T13
M

equation has been correlated with tumor progression or with gallbladder cancer. In addition, the loss of \(p16\) expression was detected in 32 of 51 (62.7%) patients.

Expression of \(p16\) was reported to range between 24 and 76% in gallbladder cancer.

We examined \(p16\) protein expression by immunohistochemistry in various types of cancer, including gallbladder cancer. We examined \(p16\) protein expression by immunohistochemistry in 51 cases of gallbladder cancer. Loss of \(p16\) protein expression has been reported to range between 24 and 76% in gallbladder cancer\(^{14,18,20,23}\). In our study, the loss of \(p16\) expression was detected in 32 of 51 (62.7%) patients with gallbladder cancer. In addition, the loss of \(p16\) expression has been correlated with tumor progression or with decreased survival among patients with carcinoma of the lung, pancreas and esophagus, and malignant melanoma\(^{21,22,24}\). The correlation between \(p16\) expression and clinicopathological factors is controversial. Ma et al\(^{15}\) have reported that decreased expression of \(p16\) is correlated with pathological grade and tumor progression in gallbladder carcinoma. However, Shi et al\(^{16}\) have reported that loss of \(p16\) protein expression is not significantly associated with any clinicopathological factors or survival. Quan et al\(^{23}\) have reported that the loss of \(p16\) expression is not associated with pathological grade. We also failed to find any association between the loss of \(p16\) expression and clinicopathological parameters.

The mechanisms of inactivation of the \(p16\) gene are homozgyous deletion, LOH, promoter hypermethylation, rearrangement, and intragenic mutation.

Homozgyous deletions are important for complete inactivation of tumor suppressor genes\(^{13}\). Previous investigators have evaluated homozgyous deletion of the \(p16\) gene in a small series of biliary tract and gallbladder cancer cell lines. Ku et al\(^{20}\) have reported that homozgyous deletion of the \(p16\) gene was detected in three of six (50%) gallbladder cell lines. Yoshida et al\(^{23}\) have reported that homozgyous deletion of the \(p16\) gene was detected in one of two gallbladder cell lines and in two biliary tract cell lines. Casa et al\(^{23}\) have reported that homozgyous deletion of the \(p16\) gene was detected in eight of nine (88.8%) biliary tract cell lines, but homozgyous deletion of the \(p16\) gene was not detected in 21 biliary tract cancers. Homozgyous deletion of the \(p16\) gene has not previously been examined in gallbladder cancer. Our study is believed to be the first report to evaluate homozgyous deletion of the \(p16\) gene. We employed quantitative real-time PCR to evaluate homozgyous deletion. In our series, homozgyous deletion of the \(p16\) gene was detected in 13 of 50...

---

**Table 3: Association between \(p16\) protein expression and 9p21-22 alterations**

| \(p16\) protein expression | Negative | Positive | \(P\) |
|-----------------------------|----------|----------|------|
| LOH (-)                     | 12       | 10       |      |
| LOH (+)                     | 20       | 9        | 0.292|

OH was estimated by allelic status at D9S171, D9S1748, D9S942, D9S974, D9S1749. LOH: Loss of heterozygosity.

**Table 4: Association between \(p16\) protein expression and \(9p21\)**

| \(p16\) protein expression | Negative | Positive | \(P\) |
|-----------------------------|----------|----------|------|
| LOH (-)                     | 16       | 16       |      |
| LOH (+)                     | 16       | 3        | 0.0146|

LOH was estimated by allelic status at D9S1748, D9S942, D9S974.

**Table 5: Association between \(p16\) immunohistochemistry and \(p16\) alterations in gallbladder cancers**

| \(p16\) immunohistochemistry | Positive | Negative | \(P\) |
|------------------------------|----------|----------|------|
| Retension                    | 3        | 3        |      |
| Hypermethylation             | 9        | 6        |      |
| LOH                          | 1        | 3        |      |
| LOH (multiple) + Hypermethylation | 2  | 8        |      |
| Multiple LOH                 | 0        | 3        |      |
| Homozgyous deletion          | 4        | 9        | \(P < 0.05\) |

LOH: Loss of heterozygosity; Multiple LOH: LOH in 9p21 at more than two loci.

**DISCUSSION**

We investigated the association between \(p16\) protein expression and \(P16\) alterations. LOH at 9p21-22 was not associated with the loss of \(p16\) expression. However, LOH at three genes (D9S1748, D9S942 and D9S974) within a coding sequence of \(p16\) was correlated with the loss of \(p16\) expression \((P < 0.05)\) (Tables 3 and 4). Furthermore, homozyous deletion of the \(p16\) gene, a combination of LOH at 9p21 and promoter hypermethylation of the \(p16\) gene, multiple LOH at 9p21 correlated with the loss of \(p16\) protein expression \((P < 0.05)\) (Table 5). Loss of \(p16\) protein expression was detected in nine of 13 tumors with homozyous deletion. LOH at 9p21 was detected in only two of 13 cases with homozyous deletion, while promoter hypermethylation of the \(p16\) gene was detected in 12 of 13 cases with homozyous deletion.
cases (26%). Previous studies have demonstrated that homozygous deletion of tumor suppressor genes plays an important role in the development and progression of some malignancies. However, in our series, homozygous deletion of the p16 gene was not associated with clinicopathological features.

Loss of p16 expression is correlated with homozygous deletion of the p16 gene in gallbladder cancer and other malignancies. Eight of nine biliary tract cell lines with homozygous deletion of the p16 gene showed loss of p16 expression, as reported by Caca et al.\(^\text{[20]}\). In our series, loss of p16 expression correlated with homozygous deletion of the p16 gene in nine of 13 tumors. In four cases, homozygous deletion of the p16 gene did not correlate with p16 protein expression. Four tumors with homozygous deletion of the p16 gene displayed moderate to strong positive staining in immunohistochemistry. These tumors showed diffuse positive staining in some areas and partial or complete loss of p16 staining in other areas. The areas which showed loss of p16 expression were not captured during microdissection, and consequently the tumors were scored as having homozygous deletion. Previous reports have shown that the loss of p16 protein expression does not always correlate with homozygous deletion of the p16 gene.\(^\text{[25]}\).

Promoter hypermethylation of p16 leads to inactivation of the gene in various cancers. In gallbladder cancer, the frequency of p16 promoter hypermethylation ranges from 24% to 56%.\(^\text{[12,29,31]}\). In our study, p16 hypermethylation was found in 72.5% (37/51) of the tumors. The frequency in our study was comparatively higher than that in previous studies. Previous studies have revealed that the frequency of p16 promoter hypermethylation is not associated with tumor progression and clinicopathological characteristics.\(^\text{[28,30]}\). Similarly, we found that p16 hypermethylation was not associated with any clinicopathological features. Some investigators have demonstrated that p16 hypermethylation is correlated with the loss of p16 expression in intraductal carcinoma of the liver, lung cancer, hepatocellular carcinoma and esophageal cancer.\(^\text{[12,33]}\). In the present study, 20 of 36 (66.6%) cases with p16 promoter hypermethylation showed a loss of p16 expression. However, there was no correlation between promoter hypermethylation and the loss of p16 expression.

We failed to detect any p16 mutations in the present study. Previous studies have shown a frequency of p16 mutation of 0%-80% in gallbladder and biliary tract cancer and cell lines.\(^\text{[9,12,14,23]}\). Ueki et al have reported that 13 of 53 (24.5%) cases of gallbladder cancer showed non-silent p16 gene mutations. Kim et al have reported that p16 mutations were detected in four of 13 (30.7%) patients with gallbladder cancer. Yoshida et al have reported that eight of 10 cases of gallbladder cancer showed p16 point mutations. These studies did not examine homozygous deletion of the p16 gene. Ku et al have reported that homozygous deletion of the p16 gene was found in three of six biliary tract cell lines, but no p16 mutation was found in the remaining three biliary tract cell lines, which did not show homozygous deletion. Caca et al\(^\text{[20]}\) have reported that p16 mutations were not found in three biliary tract cell lines and 21 biliary tract cancers, which did not show homozygous deletion of the p16 gene. In the present study, a p16 mutation was not found in any of the cases analyzed. These results suggest that the p16 mutation is associated with homozygous deletion of the p16 gene.

LOH at 9p21 has been detected in different types of tumors and cell lines.\(^\text{[36,37]}\). The frequency of LOH at 9p21 in gallbladder carcinoma ranges from 38 to 60%.\(^\text{[36,37]}\). Previous studies have demonstrated that LOH at 9p21 correlates with the loss of p16 expression in various types of cancer.\(^\text{[22,49]}\). We also investigated the association between p16 protein expression and LOH at 9p21-22 in gallbladder cancer. Although an association between LOH at 9p21-22 and p16 protein expression was not found in our study, LOH at three genes (D9S1748, D9S942 and D9S974) which are located within a coding sequence of p16, correlated with loss of p16 protein expression. The mode of p16 silencing may be explained by a modification of Knudson’s two-hit model.\(^\text{[41]}\). In cases which show the loss of p16 protein expression, LOH or promoter hypermethylation may have occurred in only one allele, and other mechanisms may also have been involved in other alleles.

In conclusion, we investigated comprehensively the mechanisms of inactivation of the p16 gene in gallbladder cancer, and the association between p16 alterations and clinicopathologic features. Although the mutation of p16 is a rare event in gallbladder cancer, homozygous deletion, LOH and promoter hypermethylation were frequent events. LOH at 9p21 correlated with loss of p16 protein expression. In addition, homozygous deletion of the p16 gene, combination of LOH and promoter hypermethylation, and multiple LOH at 9p21 significantly correlated with loss of p16 protein expression (\(P < 0.05\)). LOH at 9p21 was detected in only two of 13 cases with homozygous deletion, while promoter hypermethylation of the p16 gene was detected in 12 of 13 cases with homozygous deletion. Promoter hypermethylation of the p16 gene may have occurred as an earlier event, followed by homozygous deletion as a later event in cases of homozygous deletion. LOH and homozygous deletion may be two distinct pathways for inactivating the p16 gene in gallbladder cancer.

Our results suggest that multiple alterations of the p16 gene imply multiple mechanisms for the inactivation of the p16 gene in gallbladder cancer. The mechanisms may be important for the diagnosis and treatment of this disease.

ACKNOWLEDGMENTS

We thank Katsumi Miyahara, Yasuko Toi and Akemi Koyanagi for their technical assistance.

REFERENCES

1. Offerhaus GJA. Tumors of the gallbladder, extrahepatic bile ducts and ampulla of vater. atlas of tumor pathology. J Clin Pathol 2001; 54: 816
2. Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista G, Nervi F. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001; 51: 349-364
A gene...cancer. 2005; 160: 34-38

35 Matsuda Y, Ishida T, Matsuzawa J, Sugimura K, Asahara H. p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Cancer Res 2004; 64: 5921-5926.

36 Gazzieri S, Gouy P, Vourc'h C, Brambilla C, Br...lating craniofacial bone tumors. Int J Cancer 2005; 116: 560-565.

37 Obot E, Gao Y, Zhu D, Liao Z, Guo M, Zhang Y, Bekele BN, Gazdar AF, Wistuba II. Frequent inactivation of the INK4a/ARF locus in sporadic extrahepatic bile duct cancers and bile tract cancer cells. Int J Cancer 2002; 97: 481-488.

38 DeHaan RD, Kipp BR, Smyrk TC, Abraham SC, Roberts LR, Halling KC. An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas. Hum Pathol 2007; 38: 491-499.

39 Oda Y, Yamamoto H, Takahira T, Kobayashi C, Kawaguchi K, Tateishi N, Nozaki K, Yamaishi Y, Tanaka K, Matsuda S, Yokoyama R, Iwamoto Y, Tsujiyoshi M. Frequent alteration of p16(INK4a)/p14(ARF) and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cells. Int J Cancer 2002; 97: 481-488.

40 Cameron JL, Klimstra DS, Maitra A, Hruban RH, Argani P. Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions. Mod Pathol 2003; 16: 1082-1089.

41 Tanaka R, Wang D, Morishita Y, Inadome Y, Minami Y, Iijima T, Fukai S, Goya T, Nomura M. Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma. Cancer 2005; 103: 608-615.

42 Ku JL, Yoon KA, Kim IJ, Kim WH, Jang JY, Suh KS, Kim SW, Park YH, Hwang JH, Yoon YB, Park JB. Establishment and characterisation of six human biliary tract cancer cell lines. Br J Cancer 2002; 87: 183-197.

43 Caca K, Feisthammel J, Klee K, Tannapfel A, Witzgall M, Wittkopp C, Mosdier J, Berr F. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cells. Int J Cancer 2002; 97: 481-488.
Setoguchi T, Kato Y. Losses of heterozygosity on chromosomes 17p and 9p/18q may play important roles in early and advanced phases of gallbladder carcinogenesis. J Cancer Res Clin Oncol 1999; 125: 439-443

Mariatos G, Gorgoulis VG, Zacharatos P, Kotsinas A, Vogiatzi T, Rassidakis G, Foukas P, Liloglou T, Tiniakos D, Angelou N, Manolis EN, Veslemes M, Field JK, Kittas C. Expression of p16(INK4A) and alterations of the 9p21-23 chromosome region in non-small-cell lung carcinomas: relationship with tumor growth parameters and ploidy status. Int J Cancer 2000; 89: 133-141

Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998; 91: 4677-4685

S- Editor Zhu LH  L- Editor Kremer M  E- Editor Liu Y